Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.33 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.32 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.32 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.32 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.32 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL999548 | 1.00 | CYP3A4 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL134929 | 1.00 | CYP3A4 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL28335260 | 0.98 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL28663126 | 0.98 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Hydrochloric Acid SCHEMBL3504243 | 0.98 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL30272720 | 0.98 | TDP1 (0.48) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL5983370 | 0.98 | TDP1 (0.48) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL21373 | 0.98 | TDP1 (0.48) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| SCHEMBL3507048 | 0.95 | TDP1 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 | |
| Water SCHEMBL7066183 | 0.95 | TDP1 (0.46) | CYP3A4ALDH1A1TDP1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118191323-A | Kit for CK (Pan)/BRG 1 counterstaining and application thereof | 四川大学华西医院 | 2024-06-14 | — | — | CN | claimed |
| CN-106365243-B | Abandon a class type rainwater deep cycle purifier and purification process thereof | 徐州工程学院 | 2020-09-08 | — | — | CN | claimed |
| CN-110907255-A | Ready-to-use immunohistochemical staining solution and preparation method and application thereof | 武汉赛维尔生物科技有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-106434747-A | Method for inhibiting hepatoma carcinoma nude mouse transplantation tumor capacity through silent secretory clusterin | 南通大学附属医院 | 2017-02-22 | — | — | CN | claimed |
| US-9115251-B2 | Electrolyte membrane, fuel cell, and electrolyte membrane manufacturing method | NATIONAL UNIVERSITY CORPORATION TOYOHASHI UNIVERSITY OF TECHNOLOGY (JP) | 2015-08-25 | — | — | US | claimed |
| CN-103743902-A | Method for detecting inhibiting ability of silent GPC-3 gene transcription on hepatocellular carcinoma transplanted tumor in nude mouse | AFFILIATED HOSPITAL OF NANTONG UNIV | 2014-04-23 | — | — | CN | claimed |
| US-20120231354-A1 | ELECTROLYTE MEMBRANE, FUEL CELL, AND ELECTROLYTE MEMBRANE MANUFACTURING METHOD | NATIONAL UNIVERSITY CORPORATION TOYOHASHI UNIVERSITY OF TECHNOLOGY (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2002012898-A1 | AN IMPROVED PROCESS FOR PREPARATION OF IMMUNOCHEMICAL COMPLEX USEFUL FOR PATHOGEN DETECTION AND DETERMINATION OF THEIR ANTIBIOTIC SENSITIVITY | UNIVERSITY OF PUNE (IN) | 2002-02-14 | — | — | WO | claimed |
| US-12553882-B2 | Use of PAK4 and CRTC1 for treatment or diagnosis of brain degenerative disease | CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12527879-B2 | Ligands targeted to epidermal growth factor receptors and compositions for use in treating tumors | ACADEMIA SINICA (TW) | 2026-01-20 | — | — | US | disclosed |
| CN-119751235-A | Non-immunosuppressive FK506 analogues and uses thereof | 约翰霍普金斯大学 | 2025-04-04 | — | — | CN | disclosed |
| CN-119715527-A | Method suitable for visible light imaging and synchrotron radiation single cell imaging and application thereof | 国家纳米科学中心 | 2025-03-28 | — | — | CN | disclosed |
| CN-113614091-B | Non-immunosuppressive FK506 analogues and uses thereof | 约翰霍普金斯大学 | 2025-01-17 | — | — | CN | disclosed |
| CN-113766924-B | Use of CHP for preventing, ameliorating or treating peritoneal fibrosis | 诺麦塔制药有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-5047508-A | Monoclonal antibody to MHS-5; a new probe for sexual assault analysis | THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0345461-A2 | Mouse monoclonal antibodies to HIV-1P24 and their use in diagnostic tests | ABBOTT LABORATORIES (US) | 1989-12-13 | — | — | EP | disclosed |
| EP-0335134-A2 | Mouse monoclonal antibody to human immunodeficiency virus gp41 protein | ABBOTT LABORATORIES (US) | 1989-10-04 | — | — | EP | disclosed |
| WO-1989001153-A1 | METHODS FOR BREAST CANCER DETECTION | XOMA CORPORATION (US) | 1989-02-09 | — | — | WO | disclosed |
| EP-0251575-A1 | Hepatitis delta diagnostics and vaccines, their preparation and use | CHIRON CORPORATION (US) | 1988-01-07 | — | — | EP | disclosed |
| US-4446240-A | Pancreas specific protein systems | NERENBERG SAMUEL T | 1984-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527879-B2 | Ligands targeted to epidermal growth factor receptors and compositions for use in treating tumors | EGFR, KDR, ERBB2 | PRKCZ 487/4885MAOA 4858/4885MAOB 4849/4885 |
| US-12553882-B2 | Use of PAK4 and CRTC1 for treatment or diagnosis of brain degenerative disease | PAK4, PAK2, PAK5 | PRKCZ 110/4885MAOA 3705/4885MAOB 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.